Effects of 5HTP on the Injured Human Spinal Cord

Description

This study will assess how the serotonin precursor, 5-HTP, alter nervous system excitability and motor function in individuals with spinal cord injuries of differing chronicity and severity. Participants will visit the lab on 4 separate occasions where they will be administered four different drugs in a randomized, double-blinded, placebo-controlled crossover design.

Conditions

Spinal Cord Injuries

Talk to us

Study Overview

On this page

Study Details

Study overview

This study will assess how the serotonin precursor, 5-HTP, alter nervous system excitability and motor function in individuals with spinal cord injuries of differing chronicity and severity. Participants will visit the lab on 4 separate occasions where they will be administered four different drugs in a randomized, double-blinded, placebo-controlled crossover design.

Effects of the Serotonin Precursor, 5-hydroxytryptophan, in the Injured Human Spinal Cord

Effects of 5HTP on the Injured Human Spinal Cord

Condition
Spinal Cord Injuries
Intervention / Treatment

-

Contacts and Locations

Louisville

University of Louisville, Louisville, Kentucky, United States, 40292

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * participants must have suffered trauma to the spinal cord at least six months ago or longer
  • * individuals with damage to the nervous system other than to the spinal cord
  • * pregnant and/or breastfeeding women
  • * alcoholic participants
  • * history of seizure/epilepsy
  • * history of suicidal thoughts or behaviors
  • * known or suspected allergy to the medication ingredients
  • * cardiovascular disease including history of heart attack or heart rhythm irregularities
  • * coronary artery disease
  • * reduced liver function or disease
  • * reduced kidney function or disease
  • * lung disease
  • * comatose or depressed states due to CNS depressants
  • * endocrine dysfunction
  • * blood dyscrasias or blood related disease
  • * bone marrow depression
  • * hypocalcemia
  • * history of stomach ulcers
  • * wide angle glaucoma
  • * phenylketonuria
  • * history of tumors
  • * uncontrolled heart problems
  • * unstable psychiatric or mental disorder
  • * monoamine oxidase inhibitor therapy
  • * serotonergic antidepressants
  • * tricyclic antidepressants
  • * any type of serotonergic agonist
  • * dopamine D2 receptor antagonists
  • * amphetamine
  • * CNS depressants
  • * levodopa
  • * lithium
  • * anti-hypertensive drugs
  • * iron salts
  • * metoclopramide
  • * phenothiazine medication

Ages Eligible for Study

18 Years to 65 Years

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

University of Alberta,

Jessica D'Amico, PhD, PRINCIPAL_INVESTIGATOR, University of Alberta

Study Record Dates

2025-12-30